Spero Therapeutics' P/S lags behind the industry despite a s...
Spero Therapeutics' P/S lags behind the industry despite a strong price move. Its forecast for shrinking revenue and poor outlook justify the low P/S ratio. These conditions form a barrier for the share price at these levels.
Improved Revenues Required Before Spero Therapeutics, Inc. (NASDAQ:SPRO) Stock's 27% Jump Looks Justified
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment